期刊
JOURNAL OF FUNGI
卷 8, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/jof8080850
关键词
COVID-associated pulmonary aspergillosis; COVID-associated mucormycosis; children; cancer
Patients with COVID-19, including cancer children, are at risk of developing invasive pulmonary fungal infections. This retrospective study found that 10% of the patients diagnosed with COVID-19 had COVID-aspergillosis, and 10% had COVID-mucormycosis. The study also revealed a high mortality rate and breakthrough fungal infections in these patients, even when they were on antifungal prophylaxis.
Patients with COVID-19 are at risk of developing secondary complications such as invasive pulmonary aspergillosis and mucormycosis. This is a retrospective study including all cancer children diagnosed with COVID-19-associated pulmonary fungal infection (CAPFI) during the period 2020-2021. A total of 200 patients were diagnosed with COVID-19, out of which 21 (10%) patients were diagnosed with CAPFI, 19 patients (90%) with COVID-aspergillosis (CAPA), and 2 (10%) patients with COVID-mucormycosis (CAM). Patients with CAPFI were classified using the 2020 ECMM/ISHAM consensus criteria; proven in 2 (10%) patients, probable in 12 (57%), and possible in 7 (33%) patients. Although the hematological malignancy patients were already on antifungal prophylaxis, breakthrough fungal infection was reported in 16/21 (75%), 14 (65%) patients had CAPA while on echinocandin prophylaxis, while 2 (10%) patients had CAM while on voriconazole prophylaxis. Overall mortality was reported in 8 patients (38%) while CAPFI-attributable mortality was reported in 4 patients (20%). In conclusion, clinicians caring for pediatric cancer patients with COVID-19 should consider invasive pulmonary fungal infection, even if they are on antifungal prophylaxis, especially with worsening of the clinical chest condition. A better understanding of risk factors for adverse outcomes may improve clinical management in these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据